1 Day VERX 0.96% DJIA -0.75% S&P 500 -0.50% Business/Consumer Services -1.53% ...

Journavx received FDA approval, the agency announced on Thursday, Jan. 30. The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system, preventing ...

U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its long-awaited non-opioid painkiller. The approval of the company’s oral non ...

Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of $460. Published first on TheFly – the ultimate source ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

1 Day VERX 0.61% DJIA 0.65% S&P 500 -1.46% Business/Consumer Services 1.34% ...

Sir Keir Starmer was accused of being part of a “cover-up” of the truth about the Southport murderer as he prepared to address the nation over the state’s failure to stop the attack.

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.